Inflammatory Breast Cancer: a Single Centre Analysis

  • Gogia, Ajay (Medical Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Raina, Vinod (Medical Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Deo, Suryanarayan Vishnu (Surgical Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Shukla, Nootan Kumar (Surgical Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Mohanti, Bidhu Kalyan (Radiation Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Sharma, Daya Nand (Radiation Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences)
  • Published : 2014.04.01


Background: Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer characterized by rapidly progressive breast erythema, pain and tenderness, oedema and paeu d'orange appearance. It accounts for 1-3% of all newly diagnosed cases of breast cancer in the west. Data on IBC from India are lacking. The aim of our study was to assess the clinical-pathological parameters and outcome of IBC at, All India Institute of Medical Sciences, a large tertiary care centre. Materials and Methods: We screened 3,650 breast cancer cases registered from January 2004 to December 2012 and found 41 cases of IBC. Data included demographics as well as clinical, radiological and histopathological characteristics, and were collected from clinical case records using the International Classification of Diseases code (C-50). Patients who presented with IBC as a recurrence, or who had a neglected and advanced breast cancer that simulated an IBC were excluded from this study. Results: The median age was 45 years (range 23-66). The median duration of symptoms was 5 months. The American Joint Committee on Cancer stage (AJCC) distribution was Stage III - 26 and IV - 15 patients. Estrogen receptor (ER), progesterone receptor (PR) positivity and human epidermal growth factor receptor 2 (HER2/neu) positivity were 50%, 46% and 60%, respectively. Triple negativity was found in 15% of the cases. All the non metastatic IBC patients received anthracycline and/ or taxane based chemotherapy followed by modified radical mastectomy, radiotherapy and hormonal therapy as indicated. Pathological complete remission rate was 15%. At a median follow-up of 30 months, the 3 year relapse free survival and overall survival were 30% and 40%respectively. Conclusion: IBC constituted 1.1% of all breast cancer patients at our centre. One third of these had metastatic disease at presentation. Hormone positivity and Her2 neu positivity were found in 50% and 60% of the cases, respectively.


Inflammatory breast cancer;treatment;outcome;hormone charateristics;India


  1. Mamounas EP, Anderson SJ, Dignam JJ, et al (2012). Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol, 32, 3960-66.
  2. Perez EA, Romond EH, Suman VJ, et al (2011). Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol, 25, 3366-73.
  3. Slamon D, Eiermann W, Robert N, et al (2011). for the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med, 14, 1273-83.
  4. Turpin E, Bieche I, Bertheau P (2002). Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene, 21, 7593-7.
  5. Harris EE, Schultz D, Bertsch H (2003). Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys, 55, 1200-8.
  6. Gianni L, Eiermann W, Semiglazov, et al (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab vs neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375, 377-84.
  7. Gianni L, Pienkowski T, Im YH, et al (2012). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 1, 25-32.
  8. Gianni L, Dafni U, Gelber RD, et al (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol, 3, 236-44.
  9. Kaufmann M, Morrow M, von Minckwitz G, et al (2010). Locoregional treatment of primary breast cancer: consensus recommendations from an international expert panel. Cancer, 5, 1184-91.
  10. Kim T, Lau J, Erban J (2006). Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin Breast Cancer ,7, 386-95.
  11. Kuerer HM, Newman LA, Smith TL (1999). Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol, 17, 460-69.
  12. Low JA, Berman AW, Steinberg SM, et al (2004)Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol, 22, 4067-74.
  13. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al (2004). Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin Breast Cancer, 4, 415-9.
  14. Bear HD, Tang G, Rastogi P, et al (2012). Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med, 4, 310-20.
  15. Chevallier B, Asselain B, Kunlin A, et al (1987). Inflammatory breast cancer: Determination of prognostic factors by univariate and multivariate analysis. Cancer, 60, 897-902.<897::AID-CNCR2820600430>3.0.CO;2-S
  16. Classe JM, Bordes V, Campion L, et al (2009). Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol, 5, 726-32.
  17. Cristofanilli M, Valero V, Buzdar AU, et al (2007). Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer, 110, 1436-41.
  18. Ellis MJ, Suman VJ, Hoog J, et al (2011). Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol, 17, 2342-49.
  19. Dawood S, Merajver SD, Viens P, et al (2011). International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment. Ann Oncol, 22, 515-23.
  20. Dawood S, Ueno NT, Valero V, et al (2011). Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer, 117, 1819-23.
  21. Baselga J, Bradbury I, Eidtmann H, et al (2012). for the NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379, 633-40.
  22. Baldini E, Gardin G, Evagelista G (2004). Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer, 5, 358-63.

Cited by

  1. Comparing Role of Two Chemotherapy Regimens, CMF and Anthracycline-Based, on Breast Cancer Survival in the Eastern Mediterranean Region and Asia by Multivariate Mixed Effects Models: a Meta-Analysis vol.16, pp.14, 2015,
  2. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study vol.292, pp.3, 2015,
  3. Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer vol.2017, pp.1466-1861, 2017,
  4. Cell-based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report vol.7, pp.3, 2017,